Our Latest Stories
Your Health
July 22, 2025
Our Relentless Pursuit for New Ways to Address Disability Progression in Multiple Sclerosis
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Our Pipeline
5
Therapeutic areas
86
Compounds in clinical development
24
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
July 22, 2025
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
July 18, 2025
Press Release: Sanofi completes acquisition of Blueprint Medicines
July 17, 2025
Press Release: Sanofi announces extension of Blueprint tender offer
July 16, 2025
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration